Jane Richards

US Patent:

6713453, Mar 30, 2004

Filed:

Sep 25, 2001

Appl. No.:

09/963156

Inventors:

Heinz Redl - Vienna, AT
Walter Fuerst - Vienna, AT
Rudolf Kneidinger - Vienna, AT
Sam L. Helgerson - Altadena CA
Douglas Looker - Ft. Lupton CO
Elisabeth M. Inman - Pasadena CA
Jane P. Richards - Longmont CO
Catalina Wong - Los Angeles CA

Assignee:

Baxter Aktiengesellschaft - Vienna
Baxter International Inc. - Deerfield IL

International Classification:

A61K 3818

US Classification:

514 21, 514 12, 530402

Abstract:

A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or via an intervening substance capturing moiety such as an antibody. The conjugate can also be a recombinant fusion protein comprising a fibrin/fibrinogen binding moiety such as VEGF C-terminal domain fused to a wound-healing substance such as leptin.

US Patent:

7091325, Aug 15, 2006

Filed:

Dec 30, 2003

Appl. No.:

10/749832

Inventors:

Heinz Redl - Vienna, AT
Walter Fuerst - Vienna, AT
Rudolf Kneidinger - Vienna, AT
Sam L. Helgerson - Altadena CA, US
Douglas Looker - Ft. Lupton CO, US
Elisabeth M. Inman - Pasadena CA, US
Jane P. Richards - Longmont CO, US
Catalina Wong - Los Angeles CA, US

Assignee:

Baxter Aktiengesellschaft - Vienna
Baxter International Inc. - Deerfield IL

International Classification:

A61K 31/7088
A61K 38/17
A61K 39/395
C07H 21/00
C07K 14/435

US Classification:

5303911, 424 934, 424 94, 4241781, 514 2, 514 12, 514 44, 5303913, 5303917, 530402, 530408, 530409, 530410, 536 231

Abstract:

A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or via an intervening substance capturing moiety such as an antibody. The conjugate can also be a recombinant fusion protein comprising a fibrin/fibrinogen binding moiety such as VEGFC-terminal domain fused to a wound-healing substance such as leptin.